<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605487</url>
  </required_header>
  <id_info>
    <org_study_id>PAFCUTIII</org_study_id>
    <nct_id>NCT01605487</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria</brief_title>
  <acronym>PAFCUTIII</acronym>
  <official_title>Double-blind, Three-way Cross-over, Placebo-controlled Study to Assess the Efficacy, Safety and Mechanisms of Treatment With Rupatadine 20 mg and 40 mg in Cold Contact Urticaria (CCU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective of this study is to evaluate the efficacy of rupatadine in 20 mg and 40 mg&#xD;
      doses in the development of symptoms of cold contact urticaria. For this purpose, a Peltier&#xD;
      element-based electronic provocation device (TempTest®, emo systems GmbH, Berlin, Germany)&#xD;
      will be used. This allows skin exposure to 12 different temperatures from 4 to 42 °C&#xD;
      simultaneously in a standardized and reproducible way and thus the determination of&#xD;
      individual temperature and/or stimulation time thresholds.&#xD;
&#xD;
      In addition mediators related from activated must cells such as histamine, PAF, PGD2 should&#xD;
      be identified in the period between the application of stimulus and the appearance of&#xD;
      symptoms of cold urticaria and should be characterized qualitatively and quantitatively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Critical stimulation time threshold(CSTT) after challenge with cold</measure>
    <time_frame>Visit 1(day -14 Screening), Visit 2 (Randomization; day 0), Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49)</time_frame>
    <description>Critical stimulation time threshold (CSTT) determines the shortest stimulation time sufficient for inducing a wheal-and-flare reaction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Critical temperature threshold (CTT)after challenge with cold</measure>
    <time_frame>Visit 1(day -14 Screening), Visit 2 (Randomization; day 0), Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49)</time_frame>
    <description>Critical temperature threshold (CTT) determines the highest temperature sufficient for inducing a wheal-and-flare reaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mast cell mediator release</measure>
    <time_frame>Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability following administration of Rupatadine to patients with cold contact urticaria</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>Safety and tolerability: This includes physical examination, routine safety laboratory assessments, clinical observation, vital sings and adverse event reporting</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cold Contact Urticaria</condition>
  <arm_group>
    <arm_group_label>Rupatadine 20mg - Placebo - Rupatadine 40mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rupatadine 20mg - Rupatadine 40mg - Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Rupatadine 20mg - Rupatadine 40mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rupatadine 40mg - Placebo - Rupatadine 20mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Rupatadine 40mg - Rupatadine 20mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rupatadine 40mg - Rupatadine 20mg - Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days</description>
    <arm_group_label>Rupatadine 20mg - Placebo - Rupatadine 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days</description>
    <arm_group_label>Rupatadine 20mg - Rupatadine 40mg - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days</description>
    <arm_group_label>Placebo - Rupatadine 20mg - Rupatadine 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days</description>
    <arm_group_label>Rupatadine 40mg - Placebo - Rupatadine 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days</description>
    <arm_group_label>Placebo - Rupatadine 40mg - Rupatadine 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days</description>
    <arm_group_label>Rupatadine 40mg - Rupatadine 20mg - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed and dated&#xD;
&#xD;
          -  Reliable method of contraception for both women of childbearing potential as well as&#xD;
             man during the study and 3 months thereafter. A highly effective method of birth&#xD;
             control is defined as those which result in a low failure rate (i.e. less than 1% per&#xD;
             year) when used consistently and correctly such as implants, injectables, combined&#xD;
             oral contraceptives, some IUDs, sexual abstinence or vasectomised partner&#xD;
&#xD;
          -  Outpatients with CCU for more than 6 weeks. Urticaria symptoms must comprise wheal and&#xD;
             itch after contact cooling of the skin. Provocation should be performed by application&#xD;
             of Temptest®3.0 which allows for reproducible and standardized cold provocation tests&#xD;
             and the identification of temperature and stimulation time thresholds.&#xD;
&#xD;
          -  Age 18 and above 18 years.&#xD;
&#xD;
          -  No participation in other clinical trials 1 months before and after participation in&#xD;
             this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are inmates of psychiatric wards, prisons, or other state institutions.&#xD;
             Existing or planned placement in an institution after ruling according to § 40 passage&#xD;
             1, number 4 AMG (Arzneimittelgesetz).&#xD;
&#xD;
          -  The presence of permanent severe diseases, especially those affecting the immune&#xD;
             system, except urticaria and cold urticaria&#xD;
&#xD;
          -  The presence of permanent gastrointestinal condition which may influence the oral&#xD;
             therapy (chronic diarrhoea diseases, congenital malformations or surgical mutilations&#xD;
             of gastrointestinal tract)&#xD;
&#xD;
          -  History or presence of epilepsy, significant neurological disorders, cerebrovascular&#xD;
             attacks or ischemia&#xD;
&#xD;
          -  History or presence of myocardial infarction or cardiac arrhythmia which requires drug&#xD;
             therapy&#xD;
&#xD;
          -  ECG alterations of repolarisation (QTc prolongations &gt; 450ms)&#xD;
&#xD;
          -  Blood pressure &gt;180/100 mmHg and/or heart rate &gt;100/min.&#xD;
&#xD;
          -  Evidence of significant hepatic or renal disease (GOT and/or GPT 3 times above the&#xD;
             upper reference value, serum creatinine 1.5 times above the upper reference value)&#xD;
&#xD;
          -  History of hypersensitivity or allergic reaction to rupatadine or its ingredients or&#xD;
             any other antihistamine compounds.&#xD;
&#xD;
          -  Presence of active cancer which requires chemotherapy or radiation therapy&#xD;
&#xD;
          -  Presence of lactose and galactose intolerance or with glucose-galactose malabsorption&#xD;
&#xD;
          -  Simultaneous chronic spontaneous or physical urticaria that could interfere CCU&#xD;
             clinical assessment&#xD;
&#xD;
          -  Intake of antihistamines or antileukotrienes within 7 days before beginning of the&#xD;
             study&#xD;
&#xD;
          -  Intake of oral or depot corticosteroids within 14 days prior to screening visit&#xD;
&#xD;
          -  Use of systemic immunosupressants/immunomodulators like cyclosporine A, dapsone,&#xD;
             methotrexate, mycophenolate, chloroquine, and comparable drugs within 28 days prior to&#xD;
             screening visit.&#xD;
&#xD;
          -  Use of ketoconazole, erythromycin or potential inhibitors of the isoenzyme CYP3A4 of&#xD;
             the cytochrome P450.&#xD;
&#xD;
          -  Currently abusing drugs or alcohol&#xD;
&#xD;
          -  Unwilling or unable to comply with the protocol&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karoline Krause, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology and Allergy</name>
      <address>
        <city>Charité - Universitätsmedizin Berlin</city>
        <state>Charitéplatz 1</state>
        <zip>10117 Berlin</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Marina Abajian</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproheptadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

